target directory

the study targets the combined therapeutic effects of n acetylcysteine nac and eh 301 a combination of nicotinamide riboside and pterostilbene in conjunction with riluzole to potentially slow disease progression and improve symptoms in patients with amyotrophic lateral sclerosis als clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.